Central Depository Services

Similar documents
Central Depository Services

Central Depository Services

BLS International Services

Multi Commodity Exchange

Healty cigarette-driven growth

Intellect Design Arena

Crompton Greaves Consumer Electricals

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

Crompton Greaves Consumer Electricals

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

J. Kumar Infraprojects

Near-term pressure, but long-term outlook positive

Ahluwalia Contracts. Cautious optimism BUY RESULTS REVIEW 4QFY17 31 MAY Highlights of the quarter

NRB Bearings. Strong Show BUY RESULTS REVIEW 4QFY18 23 MAY Highlights of the quarter

Neuland Labs BUY RESULTS REVIEW 1QFY19 12 AUG 2018

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Navin Fluorine International

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

Discounting $45/bbl of realisation

Torrent Pharma BUY RESULTS REVIEW 1QFY18 01 AUG 2017

Vinati Organics BUY RESULTS REVIEW 2QFY19 29 OCT INDUSTRY CHEMICALS CMP (as on 29 Oct 2018) Rs 1,408 Target Price Rs 1,700

Hindustan Unilever BUY RESULTS REVIEW 4QFY17 18 MAY 2017

Maruti Suzuki. A Trough Quarter BUY RESULTS REVIEW 3QFY19 25 JAN CMP(as on 25 Jan 2019) Rs 6,516 Target Price Rs 7,400

PI Industries BUY RESULTS REVIEW 1QFY19 07 AUG Highlights of the quarter

Cyient. Good show, priced in NEUTRAL RESULTS REVIEW 4QFY17 21 APRIL Highlights of the quarter

Alkem Labs BUY RESULTS REVIEW 1QFY19 11 AUG story remains on-track. Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS).

Sun Pharma BUY RESULTS REVIEW 1QFY19 16 AUG 2018

Multi Commodity Exchange

Gulf Oil Lubricants BUY RESULTS REVIEW 1QFY19 09 AUG Key highlights

Agrochemicals. 3QFY18E Results Preview 09 JAN Basanth Patil

Capital Goods. 3QFY18E Results Preview. 10 Jan Sujit Jain

Sonata Software. On growth path BUY RESULTS REVIEW 1QFY18 16 AUG Highlights of the quarter

Carborundum Universal

Mphasis. Growth drivers intact BUY RESULTS REVIEW 3QFY19 25 JAN 2019

Kalpataru Power Transmission

Alkem Labs BUY RESULTS REVIEW 3QFY19 09 FEB CMP (as on 08 Feb 2019) Rs 1,904 Target Price Rs 2,340. Highlights of the quarter

Hindustan Petroleum Corporation

Ambuja Cement. Realisations-driven beat SELL RESULTS REVIEW 2QCY17 25 JUL Highlights of the quarter

Geared for version 3.0

Strong volumes, offset by costs

ICICI Prudential Life

Real Estate. 3QFY19E Results Preview. 11 Jan Parikshit D Kandpal, CFA

Music Broadcast. In-line but muted BUY RESULTS REVIEW 2QFY19 26 OCT Key highlights. CMP (as on 26 Oct 2018) Rs 328 Target Price Rs 387

Mahanagar Gas BUY RESULTS REVIEW 1QFY19 01 AUG Highlights of the quarter. CMP (as on 1 Aug 2018) Rs 947 Target Price Rs 1,292

Jubilant Life Sciences

Dishman Carbogen Amcis

J. Kumar Infraprojects

Exide Industries BUY RESULTS REVIEW 4QFY18 08 MAY Highlights of the quarter. CMP (as on 08 May 2018) Rs 268 Target Price Rs 298

Hero MotoCorp BUY RESULTS REVIEW 2QFY19 16 OCT CMP (as on 16 Oct 2018) Rs 2,898 Target Price Rs 3,602. Highlights of the quarter

Bajaj Auto BUY RESULTS REVIEW 1QFY18 21 JUL Highlights of the quarter

JBM Auto. Ready to take off BUY RESULTS REVIEW 1QFY19 07 AUG Key highlights

Crompton Greaves Consumer Electricals

Max Financial. Improving margins! BUY RESULTS REVIEW 4QFY18 30 MAY Highlights of the quarter

Hindustan Petroleum Corporation

Agriculture. 4QFY18E Results Preview 13 APR Madhukar Ladha

Tata Steel. JV comes to fruition BUY COMPANY UPDATE 21 SEP Other key highlights. CMP (as on 20 Sep 17) Rs 688 Target Price Rs 818

Suprajit Engineering. Synergies to accrue BUY COMPANY UPDATE 16 SEP 2016

Dr. Reddy s Labs. Misery continues SELL RESULTS REVIEW 1QFY18 28 JUL 2017

Subros BUY RESULTS REVIEW 2QFY19 30 OCT CMP (as on 29 Oct 2018) Rs 268 TP Rs 435. Key highlights

Hexaware Technologies

Dilip Buildcon. Strong comeback BUY RESULT REVIEW 1QFY19 16 AUG Highlights of the quarter. CMP (as on 16 Aug 2018) Rs 847 Target Price Rs 1,434

Pre-sales pickup key trigger

Weak numbers in peak quarter

PSP Projects. Marginal miss BUY RESULTS REVIEW 1QFY19 10 AUG 2018

Bajaj Auto NEUTRAL RESULTS REVIEW 2QFY16 23 OCT Key highlights. CMP (as on 23 Oct 2015) Rs 2,514 Target Price Rs 2,720

Coromandel International

Navin Fluorine International

Bharti Infratel BUY RESULT REVIEW 3QFY19 25 JAN 2019

NIIT Technologies. NEUTRAL Higher capex weighing on FCF RESULTS REVIEW 2QFY15 16 OCT 2014

ITC BUY RESULTS REVIEW 1QFY19 27 JUL 2018

Mindtree. Steady quarter, Upside capped NEUTRAL RESULTS REVIEW 4QFY19 18 APR INDUSTRY CMP (as on 16 Apr 2019) Rs 972 Target Price Rs 1,040

Bharat Petroleum Corporation

Brigade Enterprises. Stable performance BUY RESULTS REVIEW 2QFY19 14 NOV 2018

Radico Khaitan BUY RESULTS REVIEW 3QFY19 24 JAN 2019

Ambuja Cement. Weak numbers SELL RESULTS REVIEW 1QCY17 01 MAY 2017

Thangamayil BUY RESULTS REVIEW 2QFY19 15 NOV 2018

Reliance Industries. Timing is everything BUY COMPANY UPDATE 1 OCT 2014

Insecticides India BUY RESULTS REVIEW 4QFY17 30 MAY 2017

Construction. 4QFY18E Results Preview 14 APR Parikshit D Kandpal

Real Estate. 4QFY17E Results Preview. 13 Apr Parikshit D Kandpal

Emami NEUTRAL RESULTS REVIEW 4QFY15 14 MAY 2015

V-Guard BUY RESULTS REVIEW 3QFY19 02 FEB 2019

Margin boost through non-core book

Bharat Forge. Cyclical headwinds persist but structural story intact BUY COMPANY UPDATE 9 DEC Key takeaways

Oil & Gas. 4QFY17E Results Preview. 13 Apr Deepak Kolhe

Growth + cash flows = BUY

Weak quarter but well placed

Lupin BUY COMPANY UPDATE 12 SEP 2013

Coal India. Tough times BUY COMPANY UPDATE 22 AUG CMP (as on 21 Aug 17) Rs 238 Target Price Rs 300

IRB Infrastructure Developers

Outperformance continues

ITD Cementation (India) Ltd.

Brigade Enterprises BUY RESULTS REVIEW 2QFY16 03 NOV Highlights of the quarter. CMP (as on 03 Nov 2015) Rs 162 Target Price Rs 210

FIRSTSOURCE SOLUTIONS LTD.

CMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5

Chemicals and Fertilisers

BUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017

Residential recovery awaited

Multi Commodity Exchange

CMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62

Transcription:

INDUSTRY EXCHANGES CMP (as on 23 Apr 2018) Rs 296 Target Price Rs 415 Nifty 10,585 Sensex 34,451 KEY STOCK DATA Bloomberg CDSL IN No. of Shares (mn) 105 MCap (Rs bn) / ($ mn) 31/465 6m avg traded value (Rs mn) 207 STOCK PERFORMANCE (%) 52 Week high / low Rs 486/149 3M 6M 12M Absolute (%) (17.8) (21.7) - Relative (%) (13.1) (27.7) - SHAREHOLDING PATTERN (%) Promoters 24.00 FIs & Local MFs 47.32 FPIs 3.99 Public & Others 24.69 Source : NSE Amit Chandra amit.chandra@hdfcsec.com +91-22-6171-7345 Apurva Prasad apurva.prasad@hdfcsec.com +91-22-6171-7327 Steady growth outlook CDSL posted a muted 4QFY18 with flat revenue and lower margins. Revenue was up 0.8% QoQ to Rs 518mn (in-line with our est of Rs 518mn). Growth was led by 5.8/7.7% QoQ growth in Annual issuer charges/online data charges (KYC) offset by 3.5/2.8% fall in transaction revenue/ipo & corporate action charges respectively. Margin fell 383bps QoQ to 57.0% led by rise in employee cost, however for the full year margin expanded 517bps YoY to 59.6% in FY18. CDSL continued to gain BO market share from NSDL (46.5% in FY18, +241bps YoY). Incremental market share for CDSL stood at impressive 63% (vs 60% in FY17), which clearly indicates that DPs prefer CDSL over NSDL. CDSL has a robust business model, with (1) One-third of revenues being annuity (issuer charges is 29% of rev and 76% of total cost), (2) Embedded non-linearity, (3) Low capex requirement, (4) Excellent cash generation and (5) Huge option value from new areas like digitisation of academic records and insurance policies, e-warehouse receipts etc. Management indicated no near-term threat from the entry of corporate in the depository business (if allowed by SEBI). In fact, compulsory demat of shares of RESULTS REVIEW 4QFY18 24 APR 2018 Central Depository Services BUY private companies is a big un-tapped opportunity and will be led by regulatory push. We continue to like CDSL based on (1) Diversified revenue stream, (2) Healthy balance sheet (Net cash of Rs 4.8bn, ~79% of BS & ~16% of Mcap), and (3) High return ratios (RoE 17%, RoIC 85%). We expect CDSL revenue/ebitda/pat to grow at a CAGR of 17/21/19% over FY18-20E. We assign a P/E multiple of 33x to core earnings and add net cash to arrive at a TP of Rs 415 (40% upside from CMP). At 25/21x FY19/20E earnings we see value and maintain our BUY rating. Highlights of the quarter No of DPs/issuers stood at 594/10,628 in FY18. CDSL got SEBI approval to act as a registered transfer agent (RTA). CVL KYC records stand at 17mn (+15% YoY), created 2.2mn new KYC records. Signed with 231 academic institutions under NAD and 47 universities given LOI. Near term outlook: We expect growth to revive in 1QFY19 led by revival in transaction charges (function of robust markets). Margin will improve with growth. Financial Summary (Consolidated) YE March (Rs mn) 4QFY18 4QFY17 YoY (%) 3QFY18 QoQ (%) FY16 FY17 FY18 FY19E FY20E Net Revenues 518 383 35.1 513 0.8 1,229 1,460 1,910 2,236 2,635 EBITDA 295 191 54.5 312 (5.5) 639 794 1,137 1,370 1,665 APAT 258 234 10.4 254 1.7 680 858 1,032 1,221 1,456 Diluted EPS (Rs) 2.5 2.2 10.4 2.4 1.7 6.5 8.2 9.9 11.7 13.9 P/B (x) 6.4 5.8 5.2 4.6 4.1 P/E (x) 45.4 36.0 29.9 25.3 21.2 EV / EBITDA (x) 40.5 32.0 22.3 18.0 14.3 RoE (%) 14.2 16.1 17.2 18.3 19.5 Cash/Mcap (%) 14.3 16.0 15.6 17.4 19.5 HDFC securities Institutional Research is also available on Bloomberg HSLB <GO>& Thomson Reuters

Annual issuer charges is strong in 4Q, transaction charges was down 3.5% QoQ led by weak market conditions in 4QFY18 Annual issuer charges is annuity revenue stream, while transaction income is cyclical IPO/corporate action and CVL is semi cyclical in nature EBITDA margin dropped due to higher employee cost ~90% of the investment portfolio is in Debt MFs, stable yield resulted in higher other income Quarterly Consolidated Financials Snapshot YE March (Rs mn) 4QFY18 4QFY17 YoY (%) 3QFY18 QoQ (%) Total Revenue 518 383 35.1 513 0.8 Employee Cost 96 79 20.6 71 34.6 Technology Expenses 24 20 20.5 25 (2.9) Other Operating Expenses 102 93 10.7 105 (2.3) EBITDA 295 191 54.5 312 (5.5) Interest Cost 0 0 NM 0 NM Depreciation 27 11 150.1 18 44.0 Other Income 99 97 2.1 59 66.8 PBT 367 277 32.6 353 4.0 Tax 108 42 157.8 99 9.0 Share of Profit Loss from JV & Associates 0 0 NM 0 NM Minority Interest 1 1 (13.7) 0 225.4 RPAT 258 234 10.4 254 1.7 E/o gains (adj for tax) 0 0 NM 0 NM APAT 258 234 10.4 254 1.7 Margin Analysis MARGIN ANALYSIS (%) 4QFY18 4QFY17 YoY (bps) 3QFY18 QoQ (bps) Employee Cost % of Net Rev 18.5 20.7 (223) 13.8 464 Technology exp % of Net Rev 4.7 5.3 (57) 4.9 (18) Other Operating Exp % of Net Rev 19.8 24.2 (436) 20.4 (63) EBITDA Margin (%) 57.0 49.9 716 60.8 (383) Tax Rate (%) 29.4 15.1 1,430 28.1 134 APAT Margin (%) 49.8 61.0 (1,116) 49.4 44 Page 2

17% of the issuers are charged on folio basis and constitute ~58% of the annual issuer charges revenue Online data charges (CVL) revenue was up 7.7% QoQ and 55.8% YoY for FY18 led by robust inflow in MFs CKYC is a threat to CVL revenues but the possibility of it getting replaced is very remote. IPV (In person verification) and manual error checking remains the key strengths for CVL In fact, multiple usages of KYC data resulted in higher revenue for CVL Transaction and IPO/corporate action had a strong FY18 led by robust market conditions Segmental Revenue Analysis Segments Split (Rs mn) 4QFY18 4QFY17 YoY (%) 3QFY18 QoQ (%) FY18 FY17 YoY (%) Annual issuer charges 147 133 10.1 139 5.8 556 517 7.6 Transaction charges 123 89 38.5 127 (3.5) 440 312 40.8 IPO/corporate action charges 81 50 63.3 83 (2.8) 295 165 78.5 Online data charges 84 56 50.5 78 7.7 292 187 55.8 Others 83 56 49.0 86 (3.4) 327 278 17.8 Total 518 383 35.1 513 0.8 1,910 1,460 30.8 Segmental Revenue Contribution Segment Contribution (%) 4QFY18 4QFY17 YoY (bps) 3QFY18 QoQ (bps) FY18 FY17 YoY (bps) Annual issuer charges 28.4 34.8 (645) 27 132 29.1 35.4 (630) Transaction charges 23.7 23.1 59 25 (106) 23.0 21.4 163 IPO/corporate action charges 15.7 13.0 271 16 (58) 15.4 11.3 412 Online data charges 16.2 14.5 166 15 103 15.3 12.8 245 Others 16.1 14.6 150 17 (71) 17.1 19.0 (190) Total 100.0 100.0 100.0 100.0 100.0 Change in estimate Particulars Earlier estimates Revised estimates % change FY19E Revenue (Rs mn) 2,232 2,236 0.2 EBITDA (Rs mn) 1,400 1,370 (2.1) EBITDA margin (%) 62.7% 61.3% (143)bps APAT (Rs mn) 1,241 1,221 (1.6) FY20E Revenue (Rs mn) 2,620 2,635 0.6 EBITDA (Rs mn) 1,696 1,665 (1.8) EBITDA margin (%) 64.7% 63.2% (154)bps APAT (Rs mn) 1,475 1,456 (1.3) Page 3

No of BO Accounts, CDSL Catching Up With NSDL Growth In BO Accounts CDSL share in incremental account additions increased from 60% FY17 to 63% in FY18 CDSL has more no of DP s than NSDL due to more retail focus, whereas NSDL focus is institutional Mn NSDL CDSL 18 16 14 12 10 8 6 4 2 0 7.9 9.4 9.7 10.6 2.4 4.8 5.5 6.6 11.5 12.0 12.7 13.1 13.7 7.5 7.9 8.3 8.8 9.6 14.6 15.6 10.8 12.3 17.1 14.9 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 25% 20% 15% 10% 5% 0% NSDL 19% 15% 14% 9% 9% 6% 5% 5% 4% 5% 3% 3% FY09 FY10 FY11 FY12 FY13 FY14 CDSL 14% 12% 9% 6% 7% 5% FY15 FY16 FY17 21% 10% FY18 Source: CDSL, NSDL, HDFC sec Inst Research Source: CDSL, NSDL, HDFC sec Inst Research CDSL is more DP friendly than NSDL on various aspects like lower transaction fee for higher volume, zero fixed fees for no activity CDSL growth in BO accounts has been impressive, current market share stands at 47% CDSL Gaining Market Share From NSDL Incremental Market Share (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% NSDL CDSL NSDL CDSL 100% 23% 34% 36% 38% 39% 40% 40% 40% 41% 43% 44% 47% 77% 66% 64% 62% 61% 60% 60% 60% 59% 57% 56% 53% 70% 62% 70% 54% 48% 47% 39% 55% 56% 58% 60% 63% 30% 38% 30% 46% 52% 53% 61% 45% 44% 42% 40% 37% FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Source: CDSL, NSDL, HDFC sec Inst Research Source: CDSL, NSDL, HDFC sec Inst Research Page 4

CDSL Revenue Break-up And Assumptions CDSL Revenue (Rs mn) FY13 FY14 FY15 FY16 FY17 FY18 FY19E FY20E CAGR CAGR 17- CAGR 18-13-17 20E 20E Annual Issuer Charges 390 382 355 481 517 556 598 646 7% 8% 8% Growth % -1.9% -7.3% 35.8% 7.4% 7.6% 7.5% 8.0% % of Revenue 42.9% 43.0% 33.7% 39.2% 35.4% 29.1% 26.7% 24.5% Transaction Charges 218 199 283 258 312 440 540 668 9% 29% 23% Growth % -9.0% 42.4% -8.8% 20.9% 40.8% 22.7% 23.8% % of Revenue 24.1% 22.4% 26.9% 21.0% 21.4% 23.0% 24.2% 25.4% IPO/Corporate action 0 0 62 107 165 295 369 461 63%* 41% 25% Growth % NM NM 72.8% 54.3% 78.5% 25.0% 25.0% % of Revenue 0.0% 0.0% 5.9% 8.7% 11.3% 15.4% 16.5% 17.5% Online Data Charges 116 89 147 154 187 292 353 427 13% 32% 21% Growth % -23.0% 64.1% 4.8% 21.9% 55.8% 21.0% 21.0% % of Revenue 12.8% 10.0% 13.9% 12.5% 12.8% 15.3% 15.8% 16.2% Others 183 219 206 228 278 327 377 433 11% 16% 15% Growth % 19.4% -5.6% 10.5% 21.9% 17.8% 15.0% 15.0% % of Revenue 20.2% 24.6% 19.6% 18.6% 19.0% 17.1% 16.8% 16.4% Total 907 889 1,053 1,229 1,460 1,910 2,236 2,635 13% 22% 17% Growth % -2.0% 18.4% 16.7% 18.8% 30.8% 17.1% 17.8% *CAGR for FY15-17 Page 5

CDSL Cost Analysis and Assumptions CDSL Costing Analysis (Rs mn) FY13 FY14 FY15 FY16 FY17 FY18 FY19E FY20E CAGR CAGR CAGR 13-17 17-20E 18-20E Employee Cost 172 175 192 215 249 303 340 381 10% 15% 12% Growth % 1.8% 10.0% 11.9% 15.7% 22.0% 12.0% 12.0% % of Revenue 18.9% 19.6% 18.2% 17.5% 17.0% 15.9% 15.2% 14.4% % of Total Cost 31.2% 31.0% 31.9% 36.5% 37.3% 39.2% 39.2% 39.2% IT Cost 66 80 79 79 84 97 107 117 6% 12% 10% Growth % 21.4% -1.0% -0.2% 7.1% 15.2% 10.0% 10.0% % of Revenue 7.2% 9.0% 7.5% 6.4% 5.8% 5.1% 4.8% 4.5% % of Total Cost 11.9% 14.2% 13.1% 13.3% 12.7% 12.5% 12.3% 12.1% Other cost 180 179 207 273 287 332 372 416 12% 13% 12% Growth % -0.8% 15.6% 31.9% 5.2% 15.7% 12.1% 11.9% % of Revenue 19.9% 20.1% 19.6% 22.2% 19.7% 17.4% 16.6% 15.8% % of Total Cost 32.8% 31.8% 34.4% 46.3% 43.1% 42.9% 43.0% 42.9% IP Fund 133 129 123 23 46 41 47 55-23% 6% 16% Growth % -2.7% -4.4% -81.3% 98.8% -11.2% 16.0% 17.0% % of Revenue 14.6% 14.5% 11.7% 1.9% 3.1% 2.1% 2.1% 2.1% % of Net Profit 26.2% 26.6% 22.1% 4.0% 5.4% 4.0% 3.9% 3.8% Total Cost 550 562 601 589 666 773 866 970 5% 13% 12% Growth % 2.2% 6.9% -2.0% 13.0% 16.1% 12.0% 12.0% EBITDA 357 327 452 639 794 1,137 1,370 1,665 22% 28% 21% Growth % -8.4% 38.1% 41.5% 24.3% 43.2% 20.5% 21.5% EBITDA Margin % 39.4% 36.8% 42.9% 52.0% 54.4% 59.5% 61.3% 63.2% 1,502 880 192 bps bps bps Source: BSE, HDFC sec Inst Research Page 6

Valuation & outlook We expect CDSL revenue/ebitda/pat to increase at a CAGR of 17/21/19% over FY18-20E. EBITDA margin will expand from 59.5% in FY18 to 63.2% in FY20 led by a fixed cost business model (cost to grow at 12% CAGR over FY18-20E) RoE for the business is only 17.2%, owing to high net cash on the books (Rs 4.82bn, ~16% of Mcap). Adjusting for cash, RoIC stands at ~85% in FY18. RoIC is likely to moderate in FY19E, given the rise in core capital employed in the business (purchased office for Rs 0.7bn in FY18). We see value based on (1) Diversified revenue stream, (2) Fixed cost model, (3) Limited competition (4) Healthy balance sheet (Net cash ~79% of BS), (4) High return ratios (RoE 17%, RoIC 85%) (5) Option value of new growth engines like NAD and e- warehouse receipts (4) No capex required to fund growth, (5) Asset light model (6) Excellent operating cash generation (~77% of EBITDA and 85% of PAT). We believe the business should command higher multiple because it is less cyclical in nature vs exchanges (MCX, BSE) and brokerages (ICICI). We assign a P/E multiple of 33x (10% premium to MCX) to core earnings and add back net cash to arrive at a TP price of Rs 415 (40% upside from CMP). At P/E multiple of 25/21x FY19/20E earnings, value is imminent and we maintain our BUY rating. CDSL Valuation Table Core FY20 PAT (Rs mn) 1,169 Core P/E Multiple (x) 33 Core Mcap (Rs mn) 38,563 Net Cash (ex-liabilities) (Rs mn) 4,820 Target Mcap (Rs mn) 43,383 TP Rs 415 CMP (Rs) 296 Upside from CMP (%) 40% Page 7

Income Statement (Consolidated) YE March (Rs mn) FY16 FY17 FY18 FY19E FY20E Net Revenues (Rs mn) 1,229 1,460 1,910 2,236 2,635 Growth (%) 16.7 18.8 30.8 17.1 17.8 Employee Expenses 215 249 303 340 381 Other operating Expenses 374 417 470 526 589 EBITDA 639 794 1,137 1,370 1,665 EBITDA Margin (%) 52.0 54.4 59.5 61.3 63.2 EBITDA Growth (%) 41.5 24.3 43.2 20.5 21.5 Depreciation 42 37 69 79 86 EBIT 597 757 1,068 1,292 1,579 Other Income (Including EO Items) 716 408 347 365 395 Interest 0 0 0 0 0 PBT 1,313 1,166 1,414 1,657 1,974 Tax (Incl Deferred) 402 300 378 431 513 Minority Interest 1 8 5 5 5 RPAT 910 858 1,032 1,221 1,456 EO (Loss) / Profit (Net Of Tax) 230 0 0 0 0 APAT 680 858 1,032 1,221 1,456 APAT Growth (%) 20.5 26.1 20.3 18.4 19.2 Adjusted EPS (Rs) 6.5 8.2 9.9 11.7 13.9 EPS Growth (%) 20.5 26.1 20.3 18.4 19.2 Balance Sheet (Consolidated) YE March (Rs mn) FY16 FY17 FY18 FY19E FY20E SOURCES OF FUNDS Share Capital - Equity 1,045 1,045 1,045 1,045 1,045 Reserves 3,748 4,288 4,943 5,614 6,415 Total Shareholders Funds 4,793 5,333 5,988 6,659 7,460 Settlement guarantee fund Minority Interest 147 155 159 164 169 Total Debt 0 0 0 0 0 Net Deferred Taxes (Net) 29 (15) (19) (19) (19) Long Term Provisions & Others 5 6 8 8 8 TOTAL SOURCES OF FUNDS 4,974 5,479 6,135 6,812 7,617 APPLICATION OF FUNDS Net Block 37 55 761 761 767 LT Loans & Advances & Others 297 228 229 313 369 Total Non-current Assets 334 283 990 1,074 1,136 Debtors 130 133 189 221 260 Other Current Assets 88 122 137 157 184 Cash & Equivalents 4,978 5,512 5,585 6,228 7,002 Total Current Assets 5,196 5,767 5,911 6,605 7,446 Creditors 73 90 130 153 180 Other Current Liabilities & Provns 482 481 635 714 784 Total Current Liabilities 556 571 765 867 965 Net Current Assets 4,640 5,196 5,146 5,738 6,482 TOTAL APPLICATION OF FUNDS 4,974 5,479 6,135 6,812 7,617 Page 8

Cash Flow (Consolidated) YE March (Rs mn) FY16 FY17 FY18E FY19E FY20E Reported PBT 1,313 1,166 1,414 1,657 1,974 Non-operating & EO items (716) (408) (347) (365) (395) Interest expenses 0 0 0 0 0 Depreciation 42 37 69 79 86 Working Capital Change (258) 4 120 (34) (26) Tax Paid (402) (300) (378) (431) (513) OPERATING CASH FLOW ( a ) (21) 498 880 906 1,126 Capex (12) (50) (776) (78) (92) Free cash flow (FCF) (32) 448 104 827 1,034 Investments 0 0 0 0 0 Non-operating Income 716 408 347 365 395 INVESTING CASH FLOW ( b ) 704 358 (429) 287 303 Debt Issuance/(Repaid) 0 0 0 0 0 Interest Expenses 0 0 0 0 0 FCFE (32) 448 104 827 1,034 Share Capital Issuance 0 0 0 0 0 Dividend (314) (377) (444) (550) (655) FINANCING CASH FLOW ( c ) (314) (377) (444) (550) (655) NET CASH FLOW (a+b+c) 369 479 7 643 774 EO Items, Others 37 55 66 0 0 Closing Cash & Equivalents 4,978 5,512 5,585 6,228 7,002 Key Ratios (Consolidated) FY16 FY17 FY18E FY19E FY20E PROFITABILITY (%) GPM 82.5 83.0 84.1 84.8 85.6 EBITDA Margin 52.0 54.4 59.5 61.3 63.2 APAT Margin 55.4 58.8 54.0 54.6 55.3 RoE 14.2 16.1 17.2 18.3 19.5 RoIC (or Core RoCE) 76.4 103.3 84.5 69.1 77.1 RoCE 14.7 16.4 17.8 18.9 20.2 EFFICIENCY Tax Rate (%) 30.6% 25.7% 26.7% 26.0% 26.0% Fixed Asset Turnover (x) 0.3 0.3 0.3 0.3 0.4 Inventory (days) 0 0 0 0 0 Debtors (days) 39 33 36 36 36 Other Current Assets (days) 26 30 26 26 26 Payables (days) 22 22 25 25 25 Other Current Liab & Provns (days) 143 120 121 117 109 Cash Conversion Cycle (days) (100) (79) (84) (80) (72) Debt/EBITDA (x) 0.0 0.0 0.0 0.0 0.0 Net D/E (x) (1.0) (1.0) (0.9) (0.9) (0.9) Interest Coverage (x) NM NM NM NM NM PER SHARE DATA (Rs) EPS 6.5 8.2 9.9 11.7 13.9 CEPS 6.9 8.6 10.5 12.4 14.8 Dividend 2.5 3.0 3.5 4.4 5.2 Book Value 45.9 51.0 57.3 63.7 71.4 VALUATION P/E (x) 45.4 36.0 29.9 25.3 21.2 P/BV (x) 6.4 5.8 5.2 4.6 4.1 EV/EBITDA (x) 40.5 32.0 22.3 18.0 14.3 OCF/EV (%) (0.1) 2.0 3.5 3.7 4.7 FCF/EV (%) (0.1) 1.8 0.4 3.4 4.3 FCFE/Mkt Cap (%) (0.1) 1.4 0.3 2.7 3.3 Dividend Yield (%) 0.8 1.0 1.2 1.5 1.8 Page 9

RECOMMENDATION HISTORY CDSL 450 400 350 300 TP Date CMP Reco Target 19-Mar-18 289 BUY 425 24-Apr-18 296 BUY 415 250 200 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 Rating Definitions BUY : Where the stock is expected to deliver more than 10% returns over the next 12-month period NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12-month period SELL : Where the stock is expected to deliver less than (-)10% returns over the next 12-month period Page 10

Disclosure: We, Amit Chandra, MBA, & Apurva Prasad, MBA, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest. Any holding in stock No HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475. Disclaimer: This report has been prepared by HDFC Securities Ltd and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of HSL. Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments. HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business. HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report. HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600 HDFC Securities Limited, SEBI Reg. No.: NSE-INB/F/E 231109431, BSE-INB/F 011109437, AMFI Reg. No. ARN: 13549, PFRDA Reg. No. POP: 04102015, IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657, SEBI Research Analyst Reg. No.: INH000002475, CIN - U67120MH2000PLC152193 Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing. Page 11

HDFC securities Institutional Equities Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel,Mumbai - 400 013 Board : +91-22-6171 7330 www.hdfcsec.com Page 12